Search
Now showing items 11-20 of 43
Combination chemotherapy with low doses of weekly Carboplatin and oral Etoposide in poor risk small cell lung cancer
(1999)
Sixty patients with poor prognostic features, either with extensive disease (ED) or limited disease (LD) small cell lung cancer (SCLC), were treated on an out-patient basis with Carboplatin 80 mg/m2 weekly for 3 weeks and ...
Tropisetron in the prevention of acute nausea and vomiting in patients treated with high dose epirubicin
(1998)
Tropisetron is a novel selective antagonist of the type-3 serotonin (5- HT3) receptor, with proven efficacy in the control of emesis related to cancer treatment. Epirubicin in doses of >100 mg/m2 has a high emetogenic ...
Prognostic factors influencing complete response to treatment and survival of patients with nasopharyngeal cancer
(1998)
The identification of prognostic factors influencing local control and survival of patients with nasopharyngeal cancer (NPC) might help in pointing out those patients who would probably benefit from primary treatment. A ...
Primary extranodal non Hodgkin's lymphoma of the head and neck in adults: A clinicopathological comparison between tonsillar and non tonsillar lymphomas
(1998)
Primary extranodal NHL of the head and neck (HN-NHL) accounts for 10-20% of all cases of NHL. Despite their frequency, the natural history and biological behaviour of these lymphomas is poorly understood. In this study we ...
Paclitaxel by three-hour infusion and carboplatin in advanced carcinoma of nasopharynx and other sites of the head and neck: A phase II study conducted by the Hellenic Cooperative Oncology Group
(1997)
Background: Paclitaxel has been demonstrated to have significant activity in recurrent or metastatic head and neck cancer (HNC). In addition, the combination of paclitaxel and cisplatin is active in untreated patients with ...
Carboplatin alone compared with its combination with epirubicin and cyclophosphamide in untreated advanced epithelial ovarian cancer: A hellenic co-operative oncology group study
(1996)
We compared, in a multicentric randomised prospective study, the efficacy and toxicity of carboplatin 400 mg/m2 as a single agent (CB) to a combination of carboplatin 300 mg/m2, epirubicin 50 mg/m2 and cyclophosphamide 500 ...
Intensified carboplatin regimen with GM-CSF support in non-small cell lung cancer (NSCLC). A Hellenic Co-operative Oncology Group study (HeCOG)
(1997)
This is a continuation of a HeCOG previous trial utilizing carboplatin and vindesine in conventional doses as a non-toxic regimen provided easily on an outpatient basis in NSCLC. In the present study we investigated whether ...
Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: Preliminary results of a Hellenic Cooperative Ontology Group study
(1997)
Ninety previously untreated patients with advanced epithelial ovarian cancer (International Federation of Gynecology and Obstetrics stages IIC, III, and IV) were randomized, after initial cytoreductive surgery, to receive ...
Paclitaxel and carboplatin in inoperable non-small-cell lung cancer: A phase II study
(1997)
Background: Based on the high activity of single-agent paclitaxel and the superior one-year survival rates of patients with non-small-cell lung cancer (NSCLC) treated with carboplatin, a phase II trial was initiated using ...
Weekly alternating non-cross-resistant chemotherapy for small cell lung cancer with a good prognosis: A study of the Hellenic Cooperative Oncology Group
(1999)
This trial was conducted by the Hellenic Cooperative Oncology Group to improve the responses and survival in small cell lung cancer with a good prognosis, using a weekly intensive chemotherapy with alternated non-cross- ...